Quarterly report pursuant to Section 13 or 15(d)

SCHEDULE OF REVENUE RECOGNITION (Details)

v3.23.3
SCHEDULE OF REVENUE RECOGNITION (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Product Information [Line Items]        
Revenue related party [1] $ 300,236 $ 1,150 $ 320,895 $ 2,457
Revenue consolidated [1] 298,484 1,150 319,143 2,457
Related Party [Member]        
Product Information [Line Items]        
Revenue related party [1],[2] (1,752) (1,752)
Royalty Income [Member]        
Product Information [Line Items]        
Revenue related party [2] 5,412 1,150 13,164 2,457
Revenue consolidated [2] 4,925 1,150 12,677 2,457
Royalty Income [Member] | Related Party [Member]        
Product Information [Line Items]        
Revenue related party [2] (487) (487)
Laboratory Services [Member]        
Product Information [Line Items]        
Revenue related party [2] 7,423 10,500
Revenue consolidated [2] 6,158 9,315
Laboratory Services [Member] | Related Party [Member]        
Product Information [Line Items]        
Revenue related party [2] (1,265) (1,265)
Defense Study [Member]        
Product Information [Line Items]        
Revenue related party 4,500 14,250
Revenue consolidated 4,500 14,250
Defense Study [Member] | Related Party [Member]        
Product Information [Line Items]        
Revenue related party [2]  
Health Care, Patient Service [Member] | Precision Pathology Laboratories Services LLC [Member]        
Product Information [Line Items]        
Revenue related party [1] 248,654    
Revenue consolidated [1] 248,654 248,654
Health Care, Patient Service [Member] | Village Oaks Pathology Services P.A And Precision Pathology Laboratories Services LLC [Member]        
Product Information [Line Items]        
Revenue related party [1]     248,654
Health Care, Patient Service [Member] | Related Party [Member] | Precision Pathology Laboratories Services LLC [Member]        
Product Information [Line Items]        
Revenue related party [1],[2]    
Health Care, Patient Service [Member] | Related Party [Member] | Village Oaks Pathology Services P.A And Precision Pathology Laboratories Services LLC [Member]        
Product Information [Line Items]        
Revenue related party [1],[2]    
Histology Fees [Member] | Precision Pathology Laboratories Services LLC [Member]        
Product Information [Line Items]        
Revenue related party [1] 31,854    
Revenue consolidated [1] 31,854 31,854
Histology Fees [Member] | Village Oaks Pathology Services P.A And Precision Pathology Laboratories Services LLC [Member]        
Product Information [Line Items]        
Revenue related party [1]     31,854
Histology Fees [Member] | Related Party [Member] | Precision Pathology Laboratories Services LLC [Member]        
Product Information [Line Items]        
Revenue related party [1],[2]    
Histology Fees [Member] | Related Party [Member] | Village Oaks Pathology Services P.A And Precision Pathology Laboratories Services LLC [Member]        
Product Information [Line Items]        
Revenue related party [1],[2]    
Health Care, Other [Member] | Precision Pathology Laboratories Services LLC [Member]        
Product Information [Line Items]        
Revenue related party [1] 2,392    
Revenue consolidated [1] 2,393 2,393
Health Care, Other [Member] | Village Oaks Pathology Services P.A And Precision Pathology Laboratories Services LLC [Member]        
Product Information [Line Items]        
Revenue related party [1]     2,393
Health Care, Other [Member] | Related Party [Member] | Precision Pathology Laboratories Services LLC [Member]        
Product Information [Line Items]        
Revenue related party [1],[2]    
Health Care, Other [Member] | Related Party [Member] | Village Oaks Pathology Services P.A And Precision Pathology Laboratories Services LLC [Member]        
Product Information [Line Items]        
Revenue related party [1],[2]    
[1] The three months ended revenue for PPLS and its controlling interest entity, Village Oaks, only recognizes partial period of September 19 through September 30, 2023.
[2] As of September 18, 2023 (date of the Acquisition), royalty and laboratory services income agreements are considered related parties and eliminated upon consolidation.